The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis

References

• Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005; 44(5)587–596
   PubMed Web of Science ®Google Scholar
• Wigley FM. Clinical practice. Raynaud's phenomenon. N Engl J Med 2002; 347(13)1001–1008
   PubMed Web of Science ®Google Scholar
• LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996; 22(4)675–694
   PubMedGoogle Scholar
• Varga J, Denton CP, Wigley FM. editor. Scleroderma: From pathogenesis to comprehensive management. New York: Springer, 2012.
   Google Scholar
• Ribatti D, Crivellato E. Giulio Bizzozero and the discovery of platelets. Leuk Res 2007; 31(10)1339–1341
   PubMedGoogle Scholar
• Klinger MH. Platelets and inflammation. Anat Embryol (Berl) 1997; 196(1)1–11
   PubMedGoogle Scholar
• Kornerup KN, Page CP. The role of platelets in the pathophysiology of asthma. Platelets 2007; 18(5)319–328
   PubMed Web of Science ®Google Scholar
• Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: Clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99(5)938–945
   PubMed Web of Science ®Google Scholar
• O’Sullivan BP, Michelson AD. The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med 2006; 173(5)483–490
   PubMedGoogle Scholar
• Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3(7)425–430
   PubMed Web of Science ®Google Scholar
• Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1(9)1897–1905
   PubMed Web of Science ®Google Scholar
• Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007; 19(6)574–579
   PubMedGoogle Scholar
• Deuel TF, Senior RM, Chang D, Griffin GL, Heinrikson RL, Kaiser ET. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci USA 1981; 78(7)4584–4587
   PubMedGoogle Scholar
• Gurney D, Lip GY, Blann AD. A reliable plasma marker of platelet activation: Does it exist?. Am J Hematol 2002; 70(2)139–144
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391(6667)591–594
   PubMed Web of Science ®Google Scholar
• Chen MC, Chang HW, Wu CJ, Yang CH, Hung WC, Yeh KH, Fu M. Percutaneous transluminal mitral valvuloplasty reduces circulating soluble CD40 ligand in rheumatic mitral stenosis. Chest 2005; 128(1)36–41
   PubMedGoogle Scholar
• Vogel LA, Noelle RJ. CD40 and its crucial role as a member of the TNFR family. Semin Immunol 1998; 10(6)435–442
   PubMedGoogle Scholar
• Cognasse F, Hamzeh-Cognasse H, Lafarge S, Chavarin P, Cogné M, Richard Y, Garraud O. Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol 2007; 35(9)1376–1387
   PubMedGoogle Scholar
• Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98(4)1047–1054
   PubMed Web of Science ®Google Scholar
• Lev PR, Salim JP, Marta RF, Osorio MJ, Goette NP, Molinas FC. Platelets possess functional TGF-beta receptors and Smad2 protein. Platelets 2007; 18(1)35–42
   PubMed Web of Science ®Google Scholar
• Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011; 10(10)590–594
   PubMed Web of Science ®Google Scholar
• Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008; 47(Suppl. 5)v2–v4
   PubMedGoogle Scholar
• Matsumura Y, Murata S, Takada K, Takaoka M, Morimoto S. Involvement of transforming growth factor-beta 1 for platelets-induced stimulation of endothelin-1 production. Clin Exp Pharmacol Physiol 1994; 21(12)991–996
   PubMedGoogle Scholar
• Frayha RA, Shulman LE, Stevens MB. Hematological abnormalities in scleroderma. A study of 180 cases. Acta Haematol 1980; 64(1)25–30
   PubMedGoogle Scholar
• Price JE, Klimiuk PS, Jayson MI. In vitro platelet aggregability studies: Lack of evidence for platelet hyperactivity in systemic sclerosis. Ann Rheum Dis 1991; 50(8)567–571
   PubMedGoogle Scholar
• Shemirani AH, Nagy B, Jr, Takáts AT, Zsóri KS, András C, Kappelmayer J, Csiki Z. Increased mean platelet volume in primary Raynaud's phenomenon. Platelets 2012; 23(4)312–316
   PubMed Web of Science ®Google Scholar
• Hutton RA, Mikhailidis DP, Bernstein RM, Jeremy JY, Hughes GR, Dandona P. Assessment of platelet function in patients with Raynaud's syndrome. J Clin Pathol 1984; 37(2)182–187
   PubMedGoogle Scholar
• Wilkinson D, Vowden P, Gilks L, Latif AB, Rajah SM, Kester RC. Plasma eicosanoids, platelet function and cold sensitivity. Br J Surg 1989; 76(4)401–405
   PubMedGoogle Scholar
• Cuenca R, Fernández-Cortijo J, Lima J, Fonollosa V, Simeón CP, Pico M, Soriano B, Vilardell M. Platelet function study in primary Raynaud's phenomenon and Raynaud's phenomenon associated with scleroderma. Med Clin (Barc) 1990; 95(20)761–763
   PubMedGoogle Scholar
• Lau CS, McLaren M, Saniabadi A, Belch JJ. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol 1993; 22(3)97–101
   PubMed Web of Science ®Google Scholar
• Goodfield MJ, Orchard MA, Rowell NR. Increased platelet sensitivity to collagen-induced aggregation in whole blood patients with systemic sclerosis. Clin Exp Rheumatol 1988; 6(3)285–288
   PubMedGoogle Scholar
• Goodfield MJ, Orchard MA, Rowell NR. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br J Haematol 1993; 84(4)675–680
   PubMedGoogle Scholar
• Beretta L, Cossu M, Marchini M, Cappiello F, Artoni A, Motta G, Scorza R. A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. Arthritis Res Ther 2008; 10(5)R103
   PubMedGoogle Scholar
• Biondi ML, Marasini B. Abnormal platelet aggregation in patients with Raynaud's phenomenon. J Clin Pathol 1989; 42(7)716–718
   PubMedGoogle Scholar
• Reilly IA, Roy L, Fitzgerald GA. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J (Clin Res Ed) 1986; 292(6527)1037–1039
   PubMedGoogle Scholar
• Belch JJ, O’Dowd A, Forbes CD, Sturrock RD. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. Br J Rheumatol 1985; 24(4)346–350
   PubMedGoogle Scholar
• Friedhoff LT, Seibold JR, Kim HC, Simester KS. Serotonin induced platelet aggregation in systemic sclerosis. Clin Exp Rheumatol 1984; 2(2)119–123
   PubMedGoogle Scholar
• Dowie A, Francis JL, Roath OS, Challenor VF, Waller DG. Platelet aggregation in primary Raynaud's phenomenon and the effect of Enalapril administration. Platelets 1990; 1(1)25–27
   PubMedGoogle Scholar
• Seibold JR, Harris JN. Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon. J Rheumatol 1985; 12(1)99–103
   PubMedGoogle Scholar
• Lima J, Fonollosa V, Fernández-Cortijo J, Ordi J, Cuenca R, Khamashta MA, Vilardell M, Simeón CP, Picó M. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 1991; 18(12)1833–1836
   PubMedGoogle Scholar
• Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM, Goldblum SE. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002; 29(12)2565–2570
   PubMedGoogle Scholar
• Kahaleh MB, Osborn I, Leroy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982; 96(5)610–613
   PubMedGoogle Scholar
• Malia RG, Greaves M, Rowlands LM, Lawrence AC, Hume A, Rowell NR, Moult J, Holt CM, Lindsey N, Hughes P. Anticardiolipin antibodies in systemic sclerosis: Immunological and clinical associations. Clin Exp Immunol 1988; 73(3)456–460
   PubMedGoogle Scholar
• Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996; 55(2)122–127
   PubMedGoogle Scholar
• Kowal-Bielecka O, Kowal K, Lewszuk A, Bodzenta-Lukaszyk A, Walecki J, Sierakowski S. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005; 64(3)484–486
   PubMedGoogle Scholar
• Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981; 94(4 pt. 1)482–484
   PubMedGoogle Scholar
• Blann AD, Illingworth K, Jayson MI. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993; 20(8)1325–1330
   PubMedGoogle Scholar
• Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995; 34(9)814–819
   PubMedGoogle Scholar
• Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L, Khamashta MA, Hughes GR, Brancaccio V. The coagulation/fibrinolysis balance in systemic sclerosis: Evidence for a haematological stress syndrome. Br J Rheumatol 1997; 36(10)1045–1050
   PubMedGoogle Scholar
• Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008; 67(8)1121–1126
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003; 88(8)914–918
   PubMed Web of Science ®Google Scholar
• Cerinic MM, Valentini G, Sorano GG, D’Angelo S, Cuomo G, Fenu L, Generini S, Cinotti S, Morfini M, Pignone A, et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003; 32(5)285–295
   PubMedGoogle Scholar
• Mannucci PM, Lombardi R, Lattuada A, Perticucci E, Valsecchi R, Remuzzi G. Supranormal von Willebrand factor multimers in scleroderma. Blood 1989; 73(6)1586–1591
   PubMedGoogle Scholar
• Matucci-Cerinic M, Pignone A, Iannone F, Lotti T, Pesciullesi E, Spillantini G, Falcini F, Cagnoni M. Clinical correlations of plasma Angiotensin Converting Enzyme (ACE) activity in systemic sclerosis: A longitudinal study of plasma ACE level, endothelial injury and lung involvement. Respir Med 1990; 84(4)283–287
   PubMed Web of Science ®Google Scholar
• Scheja A, Eskilsson J, Akesson A, Wollheim FA. Inverse relation between plasma concentration of von Willebrand factor and CrEDTA clearance in systemic sclerosis. J Rheumatol 1994; 21(4)639–642
   PubMedGoogle Scholar
• Kumanovics G, Minier T, Radics J, Pálinkás L, Berki T, Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol 2008; 26(3)414–420
   PubMed Web of Science ®Google Scholar
• Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992; 11(4)375–382
   PubMedGoogle Scholar
• Marasini B, Casari S, Bestetti A, Maioli C, Cugno M, Zeni S, Turri O, Guagnellini E, Biondi ML. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. J Rheumatol 2000; 27(11)2621–2623
   PubMed Web of Science ®Google Scholar
• Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995; 22(10)1876–1883
   PubMed Web of Science ®Google Scholar
• Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992; 175(5)1227–1234
   PubMedGoogle Scholar
• Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 2009; 36(3)576–582
   PubMed Web of Science ®Google Scholar
• Riccieri VSK, Vasile M, Macrì V, Sciarra I, Iannace N, Alessandri C, Valesin G. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 2011; 29(2)s46–s52
   PubMedGoogle Scholar
• Solanilla A, Villeneuve J, Auguste P, Hugues M, Alioum A, Lepreux S, Ducroix JP, Duhaut P, Conri C, Viallard JF, et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 2009; 48(9)1036–1044
   PubMedGoogle Scholar
• Silveri F, De Angelis R, Poggi A, Muti S, Bonapace G, Argentati F, Cervini C. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001; 30(5)290–296
   PubMedGoogle Scholar
• Dunbar PR, Harrison A, Corkill MM, Neale TJ. Immunoassay of platelet-derived growth factor in the plasma of patients with scleroderma. Br J Rheumatol 1993; 32(11)966–971
   PubMedGoogle Scholar
• Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003; 15(6)772–777
   PubMedGoogle Scholar
• Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005; 44(12)1518–1524
   PubMedGoogle Scholar
• Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MI, Brenchley PE. Plasma TGF beta in systemic sclerosis: A cross-sectional study. Ann Rheum Dis 1994; 53(11)763–767
   PubMedGoogle Scholar
• Doran JP, Veale DJ. Biomarkers in systemic sclerosis. Rheumatology (Oxford) 2008; 47(Suppl. 5)v36–v38
   PubMedGoogle Scholar
• Valentini G, Romano MF, Naclerio C, Bisogni R, Lamberti A, Turco MC, Venuta S. Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients. J Autoimmun 2000; 15(1)61–66
   PubMedGoogle Scholar
• Kuwana M, Medsger TA, Jr, Wright TM. T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. J Immunol 1995; 155(5)2703–2714
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Meune C, Lemaréchal H, Weber S, Ekindjian OG, Kahan A. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann Rheum Dis 2005; 64(3)481–483
   PubMedGoogle Scholar
• Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 2004; 31(3)514–519
   PubMed Web of Science ®Google Scholar
• Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: Relationship to organ systemic involvement. Clin Rheumatol 2005; 24(2)111–116
   PubMed Web of Science ®Google Scholar
• Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay RE, Michel BA, Brühlmann P, Müller-Ladner U, et al. Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4(6)R11
   PubMedGoogle Scholar
• Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, Lafyatis R. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010; 5(8)e12106
   PubMed Web of Science ®Google Scholar
• Kamath S, Blann AD, Lip GY. Platelet activation: Assessment and quantification. Eur Heart J 2001; 22(17)1561–1571
   PubMed Web of Science ®Google Scholar
• Seibold JR. Serotonin and Raynaud's phenomenon. J Cardiovasc Pharmacol 1985; 7(Suppl. 7)S95–S98
   PubMedGoogle Scholar
• Coffman JD, Cohen RA. Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon. Clin Sci (Lond) 1994; 86(3)269–273
   PubMedGoogle Scholar
• Biondi ML, Marasini B, Bianchi E, Agostoni A. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. Int J Cardiol 1988; 19(3)335–339
   PubMedGoogle Scholar
• Klimiuk PS, Grennan A, Weinkove C, Jayson MI. Platelet serotonin in systemic sclerosis. Ann Rheum Dis 1989; 48(7)586–589
   PubMedGoogle Scholar
• Olewicz-Gawlik A, Danczak-Pazdrowska A, Klama K, Silny W, Prokop J, Mackiewicz S, Grala P, Hrycaj P. Blood serum levels of amino-terminal pro-C-type natriuretic peptide in patients with systemic sclerosis. Connect Tissue Res 2010; 51(2)83–87
   PubMed Web of Science ®Google Scholar
• Blann AD, Constans J, Carpentier P, Renard M, Satger B, Guérin V, Boisseau MR, Neau-Cransac N, Conri C. Soluble P selectin in systemic sclerosis: Relationship with von Willebrand factor, autoantibodies and diffuse or localised/limited disease. Thromb Res 2003; 109(4)203–206
   PubMedGoogle Scholar
• Sfikakis PP, Charalambopoulos D, Vaiopoulos G, Mavrikakis M. Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. Clin Rheumatol 1999; 18(1)28–32
   PubMedGoogle Scholar
• Gruschwitz MS, Hornstein OP, von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38(2)184–189
   PubMedGoogle Scholar
• Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993; 61(5–6)239–246
   PubMed Web of Science ®Google Scholar
• Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: A comparative study. Blood Coagul Fibrinolysis 2007; 18(4)297–302
   PubMedGoogle Scholar
• Polidoro L, Barnabei R, Giorgini P, Petrazzi L, Ferri C, Properzi G. Platelet activation in patients with the Raynaud's Phenomenon. Intern Med J 2010; 42(5)531–535
   Google Scholar
• Sakamoto K, Houya I, Inoue K, Tanaka M, Suzuki T, Sakamoto Y, Matsuo H. An imbalance in plasma prostanoids in patients with Raynaud's phenomenon and pulmonary vasospasm. Eur Respir J 1999; 13(1)137–144
   PubMedGoogle Scholar
• Young V, Ho M, Vosper H, Belch JJ, Palmer CN. Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology (Oxford) 2002; 41(8)869–875
   PubMedGoogle Scholar
• Oyabu C, Morinobu A, Sugiyama D, Saegusa J, Tanaka S, Morinobu S, Tsuji G, Kasagi S, Kawano S, Kumagai S. Plasma platelet-derived microparticles in patients with connective tissue diseases. J Rheumatol 2011; 38(4)680–684
   PubMedGoogle Scholar
• Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, Jüngel A, Beyer C, Krönke G, Zwerina J, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208(5)961–972
   PubMed Web of Science ®Google Scholar
• Piguet PF, Vesin C. Pulmonary platelet trapping induced by bleomycin: Correlation with fibrosis and involvement of the beta 2 integrins. Int J Exp Pathol 1994; 75(5)321–328
   PubMedGoogle Scholar
• Piguet PF, Kaufman S, Barazzone C, Muller M, Ryffel B, Eugster HP. Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis. Int J Exp Pathol 1997; 78(1)43–48
   PubMedGoogle Scholar
• Komura K, Fujimoto M, Yanaba K, Matsushita T, Matsushita Y, Horikawa M, Ogawa F, Shimizu K, Hasegawa M, Takehara K, et al. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 2008; 67(6)867–872
   PubMed Web of Science ®Google Scholar
• Jones EW, Hawkey CJ. A thromboxane synthetase inhibitor in Raynaud's phenomenon. Prostaglandins Leukot Med 1983; 12(1)67–71
   PubMedGoogle Scholar
• Belch JJ, Cormie J, Newman P, McLaren M, Barbenel J, Capell H, Leiberman P, Forbes CD, Prentice CR. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: A double-blind trial. Br J Clin Pharmacol 1983; 15(Suppl. 1)113S–116S
   PubMedGoogle Scholar
• Coffman JD, Rasmussen HM. Effect of thromboxane synthetase inhibition in Raynaud's phenomenon. Clin Pharmacol Ther 1984; 36(3)369–373
   PubMedGoogle Scholar
• Luderer JR, Nicholas GG, Neumyer MM, Riley DL, Vary JE, Garcia G, Schneck DW. Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon. Clin Pharmacol Ther 1984; 36(1)105–115
   PubMedGoogle Scholar
• Rustin MH, Grimes SM, Kovacs IB, Cooke ED, Bowcock SA, Sowemimo-Coker SO, Turner P, Kirby JD. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome. Eur J Clin Pharmacol 1984; 27(1)61–65
   PubMedGoogle Scholar
• Beckett VL, Conn DL, Fuster V, Osmundson PJ, Strong CG, Chao EY, Chesebro JH, O’Fallon WM. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 1984; 27(10)1137–1143
   PubMedGoogle Scholar
• Tindall H, Tooke JE, Menys VC, Martin MF, Davies JA. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon. Eur J Clin Invest 1985; 15(1)20–23
   PubMedGoogle Scholar
• Destors JM, Gauthier E, Lelong S, Boissel JP. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon. Angiology 1986; 37(8)565–569
   PubMedGoogle Scholar
• van der Meer J, Wouda AA, Kallenberg CG, Wesseling H. A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon. VASA Suppl 1987; 18: 71–75
   PubMedGoogle Scholar
• Lau CS, Khan F, McLaren M, Bancroft A, Walker M, Belch JJ. The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. Rheumatol Int 1991; 11(4–5)163–168
   PubMedGoogle Scholar
• Pancera P, Sansone S, Secchi S, Covi G, Lechi A. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon. J Intern Med 1997; 242(5)373–376
   PubMed Web of Science ®Google Scholar
• Easter MJ, Marshall JM. Contribution of prostanoids to endothelium-dependent vasodilatation in the digital circulation of women with primary Raynaud's disease. Clin Sci (Lond) 2005; 109(1)45–54
   PubMedGoogle Scholar
• Tohgi H, Tamura K, Kimura B, Kimura M, Suzuki H. Individual variation in platelet aggregability and serum thromboxane B2 concentrations after low-dose aspirin. Stroke 1988; 19(6)700–703
   PubMedGoogle Scholar
• Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest, 1979; 63(3)532–535
   PubMed Web of Science ®Google Scholar
• Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992; 23(10)1400–1403
   PubMed Web of Science ®Google Scholar
• Moncada S. Adventures in vascular biology: A tale of two mediators. Philos Trans R Soc Lond B Biol Sci 2006; 361(1469)735–759
   PubMedGoogle Scholar
• Agache I, Radoi M, Duca L. Platelet activation in patients with systemic scleroderma – Pattern and significance. Rom J Intern Med 2007; 45(2)183–191
   PubMedGoogle Scholar
• Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28(3)s39–s42
   PubMedGoogle Scholar
• Takehara K, Grotendorst GR, Silver R, LeRoy EC. Dipyridamole decreases platelet-derived growth factor levels in human serum. Arteriosclerosis 1987; 7(2)152–158
   PubMedGoogle Scholar
• Takehara K, Igarashi A, Ishibashi Y. Dipyridamole specifically decreases platelet-derived growth factor release from platelets. Pharmacology 1990; 40(3)150–156
   PubMedGoogle Scholar
• McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, Black CM, Maddison PJ. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988; 47(1)43–47
   PubMed Web of Science ®Google Scholar
• Wigley FM, Wise RA, Malamet R, Scott TE. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm. Arthritis Rheum 1987; 30(3)281–286
   PubMedGoogle Scholar
• Malamet R, Wise RA, Ettinger WH, Wigley FM. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. Am J Med 1985; 78(4)602–608
   PubMedGoogle Scholar
• Moriau M, Lavenne-Pardonge E, Crasborn L, von Frenckell R, Col-Debeys C. Treatment of the Raynaud's phenomenon with piracetam. Arzneimittelforschung 1993; 43(5)526–535
   PubMedGoogle Scholar
• Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40(9)1038–1043
   PubMed Web of Science ®Google Scholar
• Stucker O, Pons C, Duverger JP, Drieu K, D’Arbigny P. Effect of Ginkgo biloba extract (EGb 761) on the vasospastic response of mouse cutaneous arterioles to platelet activation. Int J Microcirc Clin Exp 1997; 17(2)61–66
   PubMedGoogle Scholar